Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
J, REDUCE-IT patients were in the trial for an average of 4.9 years and did not stop for efficacy at interim checkpoint 1 and interim checkpoint 2. However, you expect convincing curve separation within one year with much fewer patients in each arm in MITIGATE than in REDUCE-IT. What's the logic?
could, you have to sell your great idea to BP, not here.
zip, the selloff is due to the market, not AMRN specific. To call a bottom in AMRN, you need to call a bottom in the stock market as well.
"generic drugs that relate to Vascepa the only thing you get are 10 different versions of generic lovaza."? That's consumer fraud and violating patients' right to the truth which might lead to a false sense of CVD protection.
"Seeing revenues growing by $100,000 or $200,000 each quarter"? That's not enough to move the stock price for sure.
tke, CVS Health includes the company's retail business, which continues to be called CVS/pharmacy; its pharmacy benefit management business, which is known as CVS/caremark. Sounds like CVS pharmacy might still stock GV as it tries to maximize its profit potential. Not every entity thinks like us, long-suffering AMRN shareholders.
john, blame the guy who was with the company for over a decade, not KM.
hay, check IBB please.
Most small biotechs are weak this morning, so it's not AMRN specific.
"24% position"?
hayward, tremendous respect for your honesty regarding:
"Looks like myself along with XXX were wrong never seems to fail !"
rose, let's hope with new investor Denner and new CEO KM, AMRN becomes the new safe haven stock going forward.
"ready to add more drugs to the cardio group, with no caps on cost so long as they can enter into a race for either first- or best-in-class status in a key field."
“We look at lots of different assets,” Li responded, and follow up on those drugs that can have a major impact on patients’ lives. “I don’t know we’re constrained or contained by a certain size; it’s unmet need.”
With that kind of open checkbook strategy, it’s clear that Merck plans to remain at the bargaining table for some time to come.
https://endpts.com/fresh-off-an-11-5b-cardio-wager-merck-promises-investors-a-megablockbuster-future-in-a-return-to-the-glory-days/
dogn, that's the same webinar posted last month. This video should be played in all hospitals and doctors' office waiting rooms, sponsored by Amarin. Scripts will go thru the roof.
Thanks duke. No GL listed?
FFS, "a sympathy move to the the biotech index gamma squeeze on OE and the first of the month?" You could have posted the statement before the market opened instead of after the market closed on Friday.
The last thing I want now is to have FFS posting bullish comments. Please don't do it.
Kiwi, I sold it and took a loss. I hope it works out for you as you have a low cost basis.
jas, JT has zero impact on the outcome of REDUCE-IT trial results. The trial would have continued to run thru its completion and achieve the same RRR if you were the CEO.
liz, why couldn't JT do a bit of basic financial due diligence before signing on with a partner like Edding? Is JT's IQ really that low? Sure glad he's no longer in charge.
Not in dollar ($) term.
could, you should email Lisa with all your constructive suggestions such as "Amarin should be owned by BP", etc., since your ousting JT email worked like a charm.
study, thanks for the update. I have checked with our very helpful Amarin EVP, Lisa. She has clarified the situation with the following reply:
***
ggwpq,
Can you help me with where you saw this? I’d like to reach out and correct. If it was from the hearing itself I realize it can be confusing so let me try to clarify. This is not a rejection, it is a second ACD request. A second ACD means that the committee was still not able to reach a final recommendation and will require further consultation with stakeholders. The provision of a second ACD is not uncommon for innovative treatments seeking NHS access in the UK. We are encouraged by NICE’s diligent efforts to work alongside us and are driven and determined to have the greatest impact possible on reducing cardiovascular risk for patients. We are confident that by working effectively and proactively through the NICE process we will be able to ensure patients in England are able to access this life-saving medicine.
Hope this helps,
Lisa
***
lizzy, for EU, it's either GIA or partnership as you can't force a buyer if nobody is willing to buy. JT explained that partnership didn't make sense because V would become the 4th or 5th drug in Euro BP's sales bag (think Kowa) and as a result, the resulting shared profit wouldn't be much. For an example of EU partnership gone wrong, just look at the pathetic sales of ESPR's cardio drug in EU with its EU partner Daiichi Sankyo.
https://www.esperion.com/news-releases/news-release-details/esperion-announces-agreement-daiichi-sankyo-europe-dse
could, "The sooner AMRN is acquired by BP the better and the more money they will make."? You could insert any other hundreds of biotech names in place of AMRN, your statement would still hold true. If your statement only holds true for AMRN, you might be onto something.
The EV is closer to $.8 bil than $1.8 bil.
" RIT patents were already challenged and declared not obvious by Du." Not true. Du said no comment on RIT patent validity only.
I don't understand why some pharmas are so skillful in settlements while JT is such a dumbass.
https://endpts.com/novartis-sandoz-settles-with-novo-nordisk-for-2024-launch-of-third-victoza-generic/?utm_medium=email&utm_campaign=41%20-%20Eli%20Lilly%20partner%20slaps%20back%20at%20Pfizers%20claims%20of%20trade%20secret%20theft%20Moderna%20adds%20sumo%20to%20its%20major%20league%20advertising%20lineup%20Basic&utm_content=41%20-%20Eli%20Lilly%20partner%20slaps%20back%20at%20Pfizers%20claims%20of%20trade%20secret%20theft%20Moderna%20adds%20sumo%20to%20its%20major%20league%20advertising%20lineup%20Basic+CID_902e31dbd74f038f227e161c6c7bc00e&utm_source=ENDPOINTS%20emails&utm_term=Novartis%20Sandoz%20settles%20with%20Novo%20Nordisk%20for%202024%20launch%20of%20third%20Victoza%20generic
I would rather pay for brand drug:
https://endpts.com/amid-inspection-and-recall-woes-aurobindo-to-shut-down-nj-site-in-april/
"lawsuit over R-IT patent infringment." is no big deal for generics whose business models are revolved around lawsuits and filing sNDA. All you need is one generic who files an sNDA, the other leeches would follow.
The settlement with Hikma is meaningless as far as we still have to compete with Dr. Reddy's and Apotex' GV.
Kiwi, you said "Anyone with their LDL cholesterol under 100 mg/ dl on generic statin therapy is unlikely to add a PCSK9. So you can’t consider PCSK9’s as a statin add on". However, anyone with their TG under 150 mg/ dl on generic statin therapy is unlikely to add a Vascepa. But you consider Vascepa as a statin add on. Do you see the flaw in your logic on the definition of statin add-on?
Kiwi, "not really a statin add on"? So what's your estimate of the % of PCSK9 patients not taking statins?
Kiwi, as you know NVS paid $10B for MDCO (without outcome data, lots of PCSK9 competitions, and smaller RRR as a satin add-on), so I would say Vazkepa is worth at least $4B in EU alone.
Hypertriglyceridemia is an important modifiable risk factor that drives residual vascular risk in patients with stroke of atherothrombotic origin, even while on statin therapy:
https://n.neurology.org/content/early/2022/03/16/WNL.0000000000200112
I wish they had delayed indefinitely the high trig indication in 2012 so we don't need to deal with GV now.
Who's Karesh?
And "nice guys finish last".
It bodes well for France if it materializes!